We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Vivomedica | LSE:VVM | London | Ordinary Share | GB0030475106 | ORD 0.1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.10 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 0.10 | GBX |
Vivomedica (VVM) Share Charts1 Year Vivomedica Chart |
|
1 Month Vivomedica Chart |
Intraday Vivomedica Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 14/9/2018 | 16:16 | VivoMedica Plc. | 837 |
| 14/12/2007 | 15:31 | VVM CHARTS | 2 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 13/7/2011 14:35 by digger27 Hi guys.Just got a reply from Leonard Curtis as follows Hi John I have been told to give you an update as regards the above Company As you know Vivomedica Plc entered into liquidation on 14 September 2010 There will be no distribution to shareholders or any class of creditor There will be a report due on the anniversary date (14/09/2011) that explains what happened in the liquidation If you require anything further please let me know Kind Regards So it's all over then. I wonder what happened to the IP..bet it got snaffled up by one of the creditors..maybe Sir Christopher Evans as his fund ploughed a lot into this. Sorry for the bad news but I'm not pleased looking at my share cert for 1 million of these. |
Posted at 03/9/2010 08:37 by pc4900074200 Four days on from the meeting and not even a post card from the companyexplaining what went on at the meeting? I know we all know what did but to not have it in writing which is the right of certificated shareholders - is abysmal. With the money that we have been paying them you would think the X Directors could club together and at least cover the cost of a stamp and postcard? Another share certificate to be added to the bottom draw marked 'When in doubt about the investment take a look at these failures and think again' Or? Here's a list of Directors one should hope are NOT on any board I'm investing in now? pc W Bill Will send email, a tad busy atm, will explain in e-mail. |
Posted at 02/9/2010 11:14 by digger27 Didn't take them long to pull the website.Pity they couldn't have updated it as quick or provided a share bargain matching service.Have to keep an eye out to where DrugPrint and PathScore end up. Spent a fortune developing these and no doubt someone will pick them up for a song. |
Posted at 18/8/2010 07:52 by pc4900074200 Foot Note to post 804?Had known that there had not been anything set-up re: share trading as if that had been the case I would have had my order filled months ago! pc |
Posted at 18/8/2010 07:48 by pc4900074200 diggerI am STILL owed shares from a deal done with Barclays Stockbrokers, I will be contacting them pointing out that the MM concerned will now not be able to complete the contract undertaken between myself and them, asking for a full refund of the outstanding balance. Some light for me at the end of the tunnel as I should get a small return for some of my VVM investment? Will post result of that in due cource. pc |
Posted at 17/8/2010 12:19 by digger27 Only getting answering machine at company which is par for the course.Spoke to Michael Dillon at Leonard Curtis who told me there won't be anything left in the pot for ordinary shareholders. Employees not been paid for months and major creditors will be 1st in line. It seems Mr. Evans is a major creditor and I wouldn't mind betting he finds a home for Drugprint and Pathscore and these will emerge at some time in the future with a new company float. A lot of work went into these products and collaboration agreements weren't with any two bit company. I've taken another look at the Aim cancellation circular which was in "the best interests of the shareholders" and they gave an intention to provide shareholders with a trading mechanism ie "4 Following the Cancellation Whilst the Board believes that the Cancellation is in the Shareholders' interests, it recognises that the Cancellation will make it more difficult for Shareholders to buy and sell Ordinary Shares should they so wish. The Board intends to set up a matched bargain arrangement, provided by Brewin Dolphin, to enable Shareholders to trade the Ordinary Shares. Under this facility, it is intended that Shareholders or persons wishing to trade shares will be able to leave an indication with Brewin Dolphin that they are prepared to buy or sell at an agreed price. In the event that the matched bargain settlement facility is able to match that order with an opposite sell or buy instruction, Brewin Dolphin will contact both parties and then effect the bargain. Shareholders who do not have their own broker may need to register with Brewin Dolphin as a new client. This can take some time to process and therefore Shareholders who consider they are likely to use this facility are encouraged to commence it at the earliest opportunity. Once the facility has been arranged, details will be made available to Shareholders on the Company's website at www.vivomedica.com." Although this was an intention they never did anything about this and it can be argued that this could have affected decisions to vote for. We were never given a chance to get any of our money back so are the directors culpable here. Food for thought. |
Posted at 23/7/2010 08:06 by haff1 ..Has anyone here:1. been able to make reasonable contact with the company on how it is progressing? OR 2. been able to sell any of their share in the company since it de-listed. AND 3. if so how did you do it and what share price did you get... |
Posted at 24/3/2009 16:26 by rupert096 From my inbox today:Groucho Marx once said that he 'would not join any club that would have someone like me for a member'. It's a sentiment some companies might wish they had heeded before they joined the London Stock Exchange's club for small companies, AIM. Now, members of the AIM 'club' are heading out of the door. The number of AIM-listed companies has fallen from 1694 at the start of 2008 to 1514 today. That's a consequence not only of companies exiting the market, but also the reluctance of any new companies to join. The City hates this. It's a valuable source of advisory fees drying up in front of its eyes. But private investors should cheer. I'll explain why in a moment. But first, let's find out what has gone wrong. Here's what's really gone wrong with AIM Many times people have said to me 'the trouble with AIM is that there is too much rubbish on the market'. In other words, there are too many low quality companies with little realistic chance of rewarding investors. I don't see it that way. You just can't generalize like that because there are all sorts of companies on the market. There are companies that have been around for years and those that have little trading history; companies that need money to pursue speculative mining projects or find medical cures; companies that want to pursue an acquisition-based strategy, and companies that are happy to just plod on. But for most, the common denominator is that in order to pursue their strategy they need to raise equity finance not only when they first come to AIM but also at intervals thereafter. This requires two things. It requires a real commitment on behalf of investors to properly understand these companies and allow for the fact that the corporate journey of small companies is never smooth. Secondly, it requires that when new shares are issued, the price strikes the proper balance between risk and reward. Let me deal with the first point. It's all too apparent from my regular conversations with small company executives that their City investors make only the most cursory attempt to understand their business. They are all too ready to abandon ship at the first sign of trouble. The bigger problem, though, is the unrealistic valuations put on AIM shares in the first place... I met one savvy fund manager who says that he never buys into new issues because they rarely deliver against the forecasts made at the time. Once a company admits it is falling short of expectations, a vicious circle can quickly develop. The share price falls, it becomes impossible for the company to raise further funds, analysts conclude that it is not worthwhile to write research notes and everybody just wants out. Of course, the share price plummets. Why the AIM exodus is good for small cap investors Here's what needs to happen. All parties need to realize that the forecasts need to be set with extreme caution. This caution then needs to be reflected in the valuation put on companies when they first come to AIM. Fund managers need to drive a much harder bargain, and the companies and their advisers need to accept a lower price for newly issued shares than they would like. To put it another way, there is a price for everything. The pricing of AIM shares, especially when they first come to market, has been too high. A painful adjustment must be made and it is the companies themselves that are taking the lead... Only yesterday Bateman Engineering (ticker: BATE) decided to quit AIM. It blamed its low share price, its inability to raise equity capital, the low turnover of its shares, and the costs and responsibilities of a quotation on London stock market. Institutional shareholders are now getting annoyed. They are unhappy both at the prospect of companies going back into the private sector at a low price and at the difficulty of trading shares in a private entity. But they only have themselves to blame for failing to give these companies proper attention and support in the first place. For private investors, the good news is that the market is becoming cheaper. The hype that has at times surrounded AIM is gone and as disillusion sets in, smart investors can pick up bargain shares. The club is becoming more select and as we all know, the most exclusive clubs are always the best. The hype indicator has stopped flashing. This is a great time to be buying good quality shares while they're cheap. |
Posted at 11/3/2009 08:14 by pc4900074200 "THE KISS OF DEATH" to another share?"Will continue to inform shareholders" What a laugh? pc Their calling it a General Meeting? Its an EGM? TIDMVVM RNS Number : 6432O Vivomedica PLC 11 March 2009 VivoMedica plc ("VivoMedica" or "the Company") Proposed Cancellation of trading on AIM and Notice of General Meeting The Board of VivoMedica PLC announces that it is seeking Shareholder approval for the cancellation of admission to trading on AIM of the Company's Ordinary Shares. A General Meeting is being convened to be held on 3 April 2009 at 11.00 a.m. at the offices of Brewin Dolphin Limited, 12 Smithfield Street, London EC1A 9BD at which a resolution to seek Shareholder approval for the Cancellation will be proposed. A circular convening the General Meeting will today be posted to Shareholders and will shortly be available for download at the Company's website: www.vivomedica.com The expected timetable of events is as follows: 2009 | Despatch of this document 11 March | Last date and time for receipt of Forms of 11.00 a.m. on 1 April | Proxy | General Meeting 11.00 a.m. on 3 April | Last day for dealings on Ordinary Shares in 14 April | AIM | Expected date of cancellation of Ordinary with effect from 7.00 a.m. Shares from Admission on 15 April | The full text of the Chairman's letter contained within the circular is set out below. Definitions in this announcement shall bear the same meaning as those in the circular to Shareholders. To the holders of Ordinary Shares and, for information only, to holders of options over Ordinary Shares Dear Shareholder, PROPOSED CANCELLATION OF TRADING ON AIM AND NOTICE OF GENERAL MEETING 1. Introduction The Company has today announced that it is seeking Shareholder approval for the cancellation of admission to trading on AIM of the Company's Ordinary Shares. The purpose of this letter is to explain the rationale behind the proposed Cancellation and why the Directors unanimously consider the proposed Cancellation to be in the best interests of the Company and its Shareholders as a whole and to seek your approval for it. The notice of the General Meeting is set out at the end of this document. 2. Reason for the Cancellation of Admission Following careful consideration, the Directors have concluded that it is no longer in the best interests of the Company or its Shareholders to maintain the admission to trading on AIM of the Ordinary Shares and consider that the costs of remaining quoted on AIM far outweigh the benefits. The Company has previously announced that in order to continue with the Group's progress, further funds would be required. Following the recent well documented difficulties in the UK equity markets, it has become apparent over the last few weeks that such funds are not available from the public equity markets for a company of the size and at the stage of development of VivoMedica. This has led to significant pressure on both the Group's working capital requirements and the Group's ability to secure operational milestones. Accordingly, the Board has reviewed a number of options for alternative sources of funding. The Board has received indications that investment could be available from several investors who do not have a mandate to invest in AIM quoted companies. Your Board has therefore determined that a de-listing from AIM is a preferred course of action to give the Company a better opportunity to access the funding required to enable the Group to continue with its strategy. Furthermore the Company's quotation on AIM involves considerable direct costs to the Group, which management estimate to be in excess of GBP70,000 per annum. The Directors also believe that further substantial cost savings could be achieved in the future through revising the Company's current Board structure to ensure that it is commensurate with that of an unquoted company of the size of VivoMedica if considered appropriate. Additionally the Directors consider that VivoMedica's listing on AIM results in a disproportionate amount of senior management time being spent in meeting the AIM Rules and related regulatory requirements, including reporting, disclosure and corporate governance requirements. The Directors have given consideration to making a general offer to Shareholders by way of a rights issue or other pre-emptive issue but deem such a method to be inappropriate having regard to time and cost implications. With the above considerations in mind, the Board has decided to propose cancelling admission to trading on AIM of the Ordinary Shares to focus on securing funds to grow the inherent value of the Company. The Directors' intention is that the Company would remain a public but unlisted company. 3. Effect of the Cancellation on Shareholders The principal effects of the Cancellation would be that: | (a) there would no longer be a formal market mechanism enabling the Shareholders to trade their shares on AIM or any other market or tracking exchange (although the Company's CREST trading facility is expected to remain in place); | | (b) the Company would not be bound to announce material events, administrative charges or material transactions nor to announce interim or final results; | (c) the Company would no longer be required to comply with any of the additional specific corporate governance requirements for companies admitted to trading on AIM; and | (d) the Company will no longer be subject to the AIM Rules and Shareholders will no longer be required to vote on certain matters as provided in the AIM Rules. The Board will, however, continue to: | (a) post information relating to the Company on its website at www.vivomedica.com; | (b) continue to hold general meetings in accordance with the applicable statutory requirements and the Company's articles of association; and | | (c) continue to send Shareholders copies of the Company's audited accounts in accordance with the applicable statutory requirements. Shareholders should note that following the Cancellation the Company will remain subject to the provisions of The Takeover Code on the basis set out in those provisions. 4 Following the Cancellation Whilst the Board believes that the Cancellation is in the Shareholders' interests, it recognises that the Cancellation will make it more difficult for Shareholders to buy and sell Ordinary Shares should they so wish. The Board intends to set up a matched bargain arrangement, provided by Brewin Dolphin, to enable Shareholders to trade the Ordinary Shares. Under this facility, it is intended that Shareholders or persons wishing to trade shares will be able to leave an indication with Brewin Dolphin that they are prepared to buy or sell at an agreed price. In the event that the matched bargain settlement facility is able to match that order with an opposite sell or buy instruction, Brewin Dolphin will contact both parties and then effect the bargain. Shareholders who do not have their own broker may need to register with Brewin Dolphin as a new client. This can take some time to process and therefore Shareholders who consider they are likely to use this facility are encouraged to commence it at the earliest opportunity. Once the facility has been arranged, details will be made available to Shareholders on the Company's website at www.vivomedica.com. 5 Approving the Cancellation and General Meeting Under the AIM Rules, it is a requirement that the Cancellation must be approved by not less than 75 per cent. of the Shareholders voting in the General Meeting. Accordingly, the notice of General Meeting to be held at 11 a.m. on 3 April 2009 at the offices of Brewin Dolphin Limited, 12 Smithfield Street, London EC1A 9BD set out at the end of this Circular contains a special resolution to approve the application to the London Stock Exchange for the Cancellation. If the Resolution is approved, it is expected that the Cancellation will take effect on 15 April 2009 being at least 20 business days following the date of this letter and 5 clear business days following the date of the General Meeting. 6 Action to be taken by Shareholders A Form of Proxy for use by Shareholders in connection with the General Meeting accompanies this document. Whether or not you intend to be present at the General Meeting, you are requested to complete and sign the Form of Proxy and return it to the Company's Registrars, Capita Registrars, Proxies, The Registry, 34 Beckenham Road, Beckenham, Kent, BR3 4TU, so as to be received no later than 48 hours before the commencement of the General Meeting. Unless the Form of Proxy is received by the date and time mentioned in the instructions, it will be invalid. The completion and return of the Form of Proxy will not prevent you from attending the General Meeting and voting in person, if you so wish. 7 Recommendation The Directors consider the Resolution to be in the best interests of the Company and therefore, unanimously recommend Shareholders to vote in favour of the Resolution at the General Meeting as they intend to do in respect of their own beneficial holdings of 2,522,857, Ordinary Shares representing 1.26 per cent. of the issued share capital at the date of this document. In addition, funds managed by Merlin Biosciences Limited have undertaken to vote in favour of the Resolution in respect of their shareholdings which amount to 100,257,775 Ordinary Shares which represent approximately 49.99 per cent. of the issued share capital at the date of this document. Yours faithfully Sir Christopher Evans Chairman Contact VivoMedica plc01795 414460 Peter Leyland, Chief Executive Officer Susan Veness, Finance Director Brewin Dolphin Investment Banking (NOMAD) 0845 213 4730 Mark Brady / Alison Barrow Buchanan Communications020 7466 5000 Tim Anderson / Catherine Breen ENDS This information is provided by RNS The company news service from the London Stock Exchange END MSCKGGMFVGKGLZM |
Posted at 01/12/2008 06:20 by oneillshaun Sorry to say to guys but that is it I am done with VVM it is going nowhere fast the money raised will be burnt in a short time I am not buying another share in VVM to many other good targets out there that i can make money on, I am not selling I will hold, wish you luck.RNS Number : 9735I Vivomedica PLC 26 November 2008 VivoMedica plc (the 'Company') 26 November 2008 Notice of General Meeting The Company announces that it has today posted a circular to shareholders setting out various resolutions to be passed at the Company's General Meeting to be held on 18 December 2008. These resolutions include a proposed share capital reorganisation, which will enable a Proposed Placing of securities in order to fund the continued development of the business. The circular is available for download at the Company's website: www.vivomedica.com The full text of the Chairman's letter contained within the circular is set out below. Definitions in this announcement shall bear the same meaning as those in the circular to Shareholders. To the holders of Ordinary Shares and, for information only, to holders of options over Ordinary Shares Dear Shareholder, Proposed Share Capital Reorganisation and Notice of General Meeting 1. Introduction VivoMedica has today announced a proposal to reorganise the Company's share capital by way of the Share Capital Reorganisation conditional upon Shareholder approval to be sought at a General Meeting, details of which are set out below. The Directors stated in the Company's interim results for the six months to 30 June 2008 that in order to continue the Group's progress to date further funds would be required. The Directors consider that it would be in the best interests of the Company to seek to raise such new funds through the Proposed Placing. The Companies Act prohibits the Company from issuing Ordinary Shares at a discount to their nominal value and it will, therefore, be necessary to reorganise the share capital of the Company to allow the Proposed Placing to take place. As such, the Proposed Placing is conditional upon the passing of the Resolutions in relation to the Share Capital Reorganisation. Authority for the Share Capital Reorganisation will be sought from Shareholders at a General Meeting convened for 11.00 am on 18 December 2008. Further details of the Share Capital Reorganisation are set out below and details of the General Meeting are set out in the Notice of General Meeting at the end of this document. The purpose of this document is to give the background to and reasons for the Proposed Placing, the Share Capital Reorganisation, to explain why your Board considers that the Proposal is in the best interests of the Company and its Shareholders as a whole and to recommend that you vote in favour of the Resolutions at the forthcoming General Meeting. 2. The Placing At the Annual General Meeting, the Shareholders passed certain resolutions which, amongst other matters, authorised the Company to issue shares on a non-pre-emptive basis in connection with a financing up to an aggregate nominal amount of £4,500,000. The Board believes that it remains in the best interests of the Company to raise further finance by way of the Proposed Placing. Subject to the passing of the Resolutions, the decision as to whether or not to proceed with the Proposed Placing will be determined by the Board at such time as the Board believes it appropriate to do so, having regard to market conditions. New Ordinary Shares issued pursuant to the Proposed Placing will, if issued, rank in full for all dividends and otherwise pari passu with the then existing New Ordinary Shares. The Board will seek the advice of its Nominated Adviser and Broker in connection with the Proposed Placing and as to which potential investors New Ordinary Shares may be offered as part of the Proposed Placing. The net proceeds of the Proposed Placing will be used to continue to fund the development of our two key technologies PathscoreTM and DrugPrint® and for other general working capital purposes. 3. Background to and reasons for the Share Capital Reorganisation At the time of the Company's interim results for the six months to 30 June 2008, the Directors reported on the significant progress the Company had made towards delivering high value solutions to the pharmaceutical industry and in realising the commercial value of the Company's exclusive worldwide technology licences. We also stated that the nature of the Group's operations means that VivoMedica's future income is dependent on securing collaboration agreements and/or sales/sub-licensing contracts within the markets it currently operates in, and on developing new applications for the PathscoreTM and DrugPrint® products. As a result there can be a considerable and unpredictable variation in the timing and amount of cash inflows generated from planned product launches. We therefore announced that in order to continue the Group's progress to date, further funds would be required. The Directors therefore intend to seek to raise new funds via the Proposed Placing. 4. Details of the Share Capital Reorganisation The closing mid-market price of an Existing Ordinary Share was 0.7p on 25 November 2008, being the last dealing date prior to the publication of this document. The Company's share price is therefore below the nominal value of an Ordinary Share of 2 pence each. In effect this prohibits the Company from raising any further equity capital as, in order to comply with the Companies Act, any further shares issued would have to be issued at a price at or above the nominal value. Consequently, the Board proposes to sub-divide the shares as detailed below and reduce the nominal value of each Existing Ordinary Share to 0.1 pence per share. Resolution 1 to be proposed at the General Meeting and as set out at the end of this document, proposes that each Existing Ordinary Share of 2 pence each in nominal value be sub-divided into one New Ordinary Share of 0.1 pence each in nominal value and one new Deferred Share of 1.9 pence each in nominal value. The New Ordinary Shares of 0.1 pence each so created will continue to carry the same rights as attach to the Existing Ordinary Shares of 2 pence each (save for the reduction in nominal value). Following the Share Capital Reorganisation, the Company's authorised share capital will remain at £14,000,000 comprising 700,000,000 New Ordinary Shares and 700,000,000 Deferred Shares and the Company's issued share capital will comprise 200,555,662 New Ordinary Shares and 200,555,662 Deferred Shares. 5. Share Rights The New Ordinary Shares arising on completion of the Share Capital Reorganisation will have the same rights as the Existing Ordinary Shares, including without limitation, the same voting, dividend and other rights. The Deferred Shares will be transferable only with the consent of the Company and will not be admitted to trading on any market or exchange. The Deferred Shares will not confer on their holders any right to receive notice of any general meeting of the Company nor any right to attend, speak or vote at any such meeting. The Deferred Shares will not entitle their holders to receive any dividend or other distribution and shall on a return of assets in a winding up of the Company entitle the holders only to the repayment of the amounts paid up on such shares after the amount paid to holders of the New Ordinary Shares exceeds £700,000,000 per New Ordinary Share. The Deferred Shares will also be incapable of transfer and no share certificates will be issued in respect of them. The Directors consider that the Deferred Shares to be of no economic value. The Deferred Shares will, subject to Shareholder approval pursuant to Resolution 2 to be proposed at the General Meeting, be re-purchased by the Company, pursuant to a contract for purchase approved in accordance with Resolution 1, for 1 pence in aggregate for all such shares and following such repurchase will be cancelled. The repurchase of the Deferred Shares will be financed out of the proceeds of the issue of 1 Existing Ordinary Share by the Company to be subscribed by an existing shareholder at a subscription price equal to the nominal value of such share. 6. General Meeting A notice convening the General Meeting to be held at the offices of Buchanan Communications, 45 Moorfields, London EC2Y 9AE at 11.00 am on 18 December 2008 is set out at the end of this document. At the General Meeting, the following Resolutions will be proposed: (1) a special resolution to: (A) sub-divide each Existing Ordinary Share into one New Ordinary Share with a nominal value of 0.1 pence and one Deferred Share with a nominal value of 1.9 pence; and (B) amend the Articles to reflect the creation of the Deferred Shares; and (2) conditional on passing Resolution 1, an ordinary resolution to authorise the Directors to repurchase the Deferred Shares pursuant to a contract for purchase. 7. Action to be taken A Form of Proxy for use by Shareholders in connection with the General Meeting accompanies this document. Whether or not you intend to be present at the General Meeting, you are requested to complete and sign the Form of Proxy and return it to the Company's Registrars, Capita Registrars, Proxies, The Registry, 34 Beckenham Road, Beckenham, Kent, BR3 4TU, so as to be received no later than 48 hours before the commencement of the General Meeting. Unless the Form of Proxy is received by the date and time mentioned in the instructions, it will be invalid. The completion and return of the Form of Proxy will not prevent you from attending the General Meeting and voting in person, if you so wish. 8. Recommendation The Directors consider the Resolutions to be in the best interests of the Company and therefore, unanimously recommend Shareholders to vote in favour of the Resolutions at the General Meeting as they intend to do in respect of their own beneficial holdings of 4,322,857 Ordinary Shares representing 2.16 per cent. of the issued share capital at the date of this document. Funds managed by Merlin Biosciences Limited have undertaken to vote in favour of the Resolutions in respect of their shareholdings which amount to 100,257,775 Ordinary Shares which represent approximately 49.99 per cent. of the issued share capital at the date of this document. Yours faithfully Sir Christopher Evans Chairman Contact: Buchanan Communications 020 7466 5000 Tim Anderson / Catherine Breen Brewin Dolphin Investment Banking (NOMAD) 0845 270 8600 Mark Brady / Alison Barrow This information is provided by RNS The company news service from the London Stock Exchange |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
